Biosimilars companies urge Gottlieb to influence administration

Speaking at an FDA public hearing, representatives of biosimilars manufacturers Tuesday called on FDA Commissioner Scott Gottlieb to lobby federal agencies and Congress to address commercial practices that are limiting uptake of biosimilars. They also praised FDA’s Biosimilars Action Plan, and called for the agency to follow through with

Read the full 492 word article

User Sign In